TABLE 1.
Incidence of All Symptomatic Grade ≥ 2 Adverse Events Experienced by ≥ 10% of Patients in Either Treatment Arm by Cohort of ENGOT-OV16/NOVA
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.